Advertisement

Supportive Care in Cancer

, Volume 26, Issue 2, pp 325–326 | Cite as

Adherence to TKI in CML patients: more than reports

  • Jessica de O. Souza
  • Fernanda de O. Busato
  • Isadora Duarte Santos Frota
  • Daniel Santos Neves
  • Marcelo Renan de Deus Santos
  • David N. Olivieri
  • Carlos E. TadokoroEmail author
Letter to the editor
  • 153 Downloads

There has been much debate about reliable methodologies for measuring adherence to drug therapies for chronic diseases. Recently, our group carried out a drug adherence study [1] with chronic myeloid leukemia (CML), a clonal myeloproliferative disease characterized by the presence of the Philadelphia chromosome [2]. Tyrosine kinase inhibitors (TKI) are widely used to treat CML and have been shown to lead to long-term survival rates when administered with strict dosage regimens. Thus, assuring treatment adherence is a critical strategy to obtain successful outcomes in patients with this chronic disease.

We have posited that the clinical pharmacist can play a critical role in the present treatment plans through more frequent patient monitoring and by providing more personalized assessments of the patient’s disease status [1]. Because the characteristics of TKI treatments for CML are similar to other chronic disease treatments, an effective adherence methodology demonstrated for CML...

Notes

Funding information

This work was partially supported by a FAPES grant (0461/2015).

Compliance with ethical standards

Conflict of interest

We declare that FAPES foundation did not participate in authorship, data acquisition, analysis, decision concerning the procedures, or conclusions of the work in any form. As such, the authors of this manuscript have full control of the primary data and agree to make the data available for review by journal editors if requested.

References

  1. 1.
    Moulin, SMM, Eutrópio, JF, Souza, JO et al (2017) The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Supp care Cancer 25:951–955Google Scholar
  2. 2.
    Nowell PC (2007) Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 117(8):2033–2035.  https://doi.org/10.1172/JCI31771 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, Vergílio B, Silveira RA, Oliveira-Duarte V, Lorand-Metze I, Souza CA, Pagnano KB (2015) Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. Clinics 70(8):550–555.  https://doi.org/10.6061/clinics/2015(08)04 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Okumura LM, Antunes VD, Aguiar KSet al (2015) Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment. Pharm Pract (Granada) 13(2): 559, DOI:  10.18549/PharmPract.2015.02.559
  5. 5.
    de Almeida MH, Pagnano KB, Vigorito AC et al (2013) Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort. Acta Haematol 130(1):16–22.  https://doi.org/10.1159/000345722 CrossRefPubMedGoogle Scholar
  6. 6.
    Okumura, L.M (2017) How to report adherence to treatment as clinically relevant data - making a case of CML and TKI. Supp Care Cancer.  https://doi.org/10.1007/s00520-017-3809-2
  7. 7.
    WHO Adherence to Long-term Therapies Project (2003) Adherence to long-term therapies: evidence for action. World Health Organization, GenèveGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Jessica de O. Souza
    • 1
  • Fernanda de O. Busato
    • 2
  • Isadora Duarte Santos Frota
    • 3
  • Daniel Santos Neves
    • 4
  • Marcelo Renan de Deus Santos
    • 4
  • David N. Olivieri
    • 5
  • Carlos E. Tadokoro
    • 1
    • 2
    • 3
    • 4
    • 6
    Email author
  1. 1.Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF)Universidade Vila VelhaVila VelhaBrazil
  2. 2.Laboratory of ImmunobiologyUniversidade Vila VelhaVila VelhaBrazil
  3. 3.Programa de Pós-graduação em Ciência Animal (PPGCA)Universidade Vila VelhaVila VelhaBrazil
  4. 4.Programa de Pós-graduação em Ecologia de Ecossistemas (PPGEE)Universidade Vila VelhaVila VelhaBrazil
  5. 5.Escuela Superior de Ingeniería InformaticaUniversity of VigoVigoSpain
  6. 6.Universidade Vila Velha - Ed. BiopráticasVila VelhaBrazil

Personalised recommendations